Quantitative analysts note NWBO stock price forecast benefits from correlation to biotech innovation indices, which posted gains over the past quarter. 2025 MLB Playoff Bracket: Schedule, Scores for Divisional Series Northwest Biotherapeutics (NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, held its Annual Shareholders Meeting on June 29, 2024. Over 77% of the total shares voted, with 961.7 million votes cast out of 1.2 billion outstanding shares. Five shareholder proposals were overwhelmingly approved, including the re-election of Class I directors and the ratification of stock options and executive compensation. The company also discussed its progress and future growth opportunities, emphasizing its strong performance since the last meeting. An audio recording of the session is available on the company's website through July 7, 2024. Price action reports underline NWBO stock price forecast as potentially range-bound pending news catalysts, with the upper bound currently modeled at $0.72.